Chiron Fluvirin production
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Chiron expects a full production season in 2006-2007 of 40 mil. doses for its influenza vaccine Fluvirin, the firm says Oct. 17. The company reports it has shipped 1.5 mil. doses of this year's formulation so far but that production for the full 2005-2006 season will be lower than previously expected. Chiron says it will not provide revised total production estimates for the current season. FDA released three lots of Fluvirin Sept. 14 (1Pharmaceutical Approvals Monthly October 2005, p. 16). "Despite Chiron's lowered projections announced today, we still anticipate that there will be significantly more vaccine produced than last year," FDA said in a same-day press release...
You may also be interested in...
Approval In Brief
Pfizer's Aromasin for early breast cancer: Pfizer's oncologic Aromasin (exemestane) clears FDA Oct. 5 for adjuvant treatment of early breast cancer in patients crossing over from tamoxifen therapy. Aromasin's additional indication is for "adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer following two to three years of tamoxifen for a completion of five consecutive years of adjuvant hormonal therapy," Pfizer says. The firm's Intergroup Exemestane Study found a 31% reduced risk of recurrence in patients switching to Aromasin versus those remaining on tamoxifen. Aromasin previously was approved for advanced breast cancer in patients whose disease progressed following tamoxifen therapy...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.